Autoimmunity and thyroid dysfunction during sunitinib treatment in metastatic renal cell carcinoma
Endocrinologist, cilt.19, sa.5, ss.224-225, 2009 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 19 Sayı: 5
- Basım Tarihi: 2009
- Doi Numarası: 10.1097/ten.0b013e3181b609b6
- Dergi Adı: Endocrinologist
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.224-225
- Anahtar Kelimeler: sunitinib, autoimmunity, hypothyroidism, renal cell carcinoma
- Sağlık Bilimleri Üniversitesi Adresli: Hayır
Özet
Sunitinib, a multiple receptor tyrosine kinase inhibitor, is used in the treatment of renal cell carcinoma and gastrointestinal stromal tumors. Sunitinib-induced thyroid dysfunction has been reported; however, autoimmunity has not been thoroughly described during sunitinib treatment. In this report, we present a 57-year-old man with metastatic RCC who had transient subclinical hyperthyroidism and hypothyroidism during sunitinib therapy. He also developed anti nuclear antibody (speckled pattern) and antidouble stranded DNA positivity. © 2009 Lippincott Williams & Wilkins, Inc.